George D. Yancopoulos

Atopic dermatitis treatment candidate Dupixent jointly developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR)(NYSE: SNY) has scaled the regulatory hurdle, a day ahead of the scheduled FDA examination day. The companies said the FDA has okayed Dupixent Injection, the first...